Lv4
440 积分 2023-12-26 加入
Datopotamab–deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial
14天前
已完结
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
1个月前
已完结
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial
1个月前
已完结
Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer
1个月前
已完结
A glucocorticoid–FAS axis controls immune evasion during metastatic seeding
2个月前
已完结
Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial
3个月前
已完结
Molecular classification of hormone receptor-positive HER2-negative breast cancer
3个月前
已完结
Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial
3个月前
已关闭
Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial
3个月前
已完结
Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial
3个月前
已完结
皖公网安备34019202002308
